These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31216755)

  • 1. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.
    Reynders N; Abboud D; Baragli A; Noman MZ; Rogister B; Niclou SP; Heveker N; Janji B; Hanson J; Szpakowska M; Chevigné A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31216755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR3, a double-edged sword in tumor progression and angiogenesis.
    Billottet C; Quemener C; Bikfalvi A
    Biochim Biophys Acta; 2013 Dec; 1836(2):287-95. PubMed ID: 23994549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines.
    Shin SY; Nam JS; Lim Y; Lee YH
    J Biol Chem; 2010 Oct; 285(40):30731-40. PubMed ID: 20650898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cysteine-X-cysteine motif chemokine ligands 9, 10, and 11, their receptor CXCR3, and their possible role on the recruitment of immune cells at the maternal-conceptus interface in pigs.
    Han J; Gu MJ; Yoo I; Choi Y; Jang H; Kim M; Yun CH; Ka H
    Biol Reprod; 2017 Jul; 97(1):69-80. PubMed ID: 28859287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.
    Bikfalvi A; Billottet C
    Am J Physiol Cell Physiol; 2020 Mar; 318(3):C542-C554. PubMed ID: 31913695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR3 ligands in disease and therapy.
    Van Raemdonck K; Van den Steen PE; Liekens S; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2015 Jun; 26(3):311-27. PubMed ID: 25498524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
    Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
    Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
    Xanthou G; Duchesnes CE; Williams TJ; Pease JE
    Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CXCR3 and its ligands in renal transplant outcome.
    Dabiri S; Kariminik A; Kennedy D
    Eur Cytokine Netw; 2016 Jun; 27(2):34-40. PubMed ID: 27478077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment.
    Neo SY; Lundqvist A
    Adv Exp Med Biol; 2020; 1231():45-51. PubMed ID: 32060845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
    Berchiche YA; Sakmar TP
    Mol Pharmacol; 2016 Oct; 90(4):483-95. PubMed ID: 27512119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.
    Pan M; Wei X; Xiang X; Liu Y; Zhou Q; Yang W
    Clin Transl Oncol; 2023 Aug; 25(8):2306-2320. PubMed ID: 37076663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR3-binding chemokines: novel multifunctional therapeutic targets.
    Lazzeri E; Romagnani P
    Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):109-18. PubMed ID: 15777209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
    Müller M; Carter S; Hofer MJ; Campbell IL
    Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
    Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
    Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
    Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases.
    Tacke F; Zimmermann HW; Berres ML; Trautwein C; Wasmuth HE
    Liver Int; 2011 Jul; 31(6):840-9. PubMed ID: 21645215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.